D. E. Shaw & Co., Inc. Aveo Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.48 - $14.97 $1.06 Million - $1.87 Million	-124,680 Reduced 46.89%	141,202 $2.11 Million
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $870,708 - $1.15 Million	131,726 Added 98.19%	265,882 $2.19 Million
Q2 2022 Aug 15, 2022	BUY	$3.51 - $6.67 $272,530 - $517,885	77,644 Added 137.39%	134,156 $880,000
Q1 2022 May 16, 2022	BUY	$3.15 - $6.01 $54,224 - $103,456	17,214 Added 43.8%	56,512 $316,000
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $184,307 - $290,805	39,298 New	39,298 $184,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.